IOM calls for better tracking to end scourge of fake or poor-quality drugs

Published: Wednesday, Feb. 13 2013 7:10 p.m. MST

The scourge of fake and substandard drugs is an international issue that will require global agreement to counter it, according to a report issued Wednesday by the Institute of Medicine.

Both poorly manufactured medications and those that are not what they are presented as pose health risks, sometimes dire, to people. And they increase the cost of health care, can lead to development of drug resistance and otherwise create harm, it said.

More than 124 countries had problems with fake or substandard drugs in 2011, from product that had been diluted so it was ineffective to contamination to drugs that didn't even have the active ingredient they were supposedly built around, the report said.

The risk is greatest in developing countries, where medication often is un- or under-regulated. But even in the United States, it's problematic. The U.S. Food and Drug Administration just last month confirmed that some patients received a fake version of a cancer treatment, Avastin.

In another case cited in the report, "negligent production at a Massachusetts compounding pharmacy sickened more than 600 people, killing 44, from September 2012 to January 2013. The vast majority of problems, however, occur in developing countries where underpowered and unsafe medicines frequently compromise treatment of deadly disease and accelerate drug resistance, affecting millions," it said.

The U.S. product in question was contaminated steroids. Other cases tracked by the FDA include contaminated heparin, a blood thinner, that killed more than 60 people. That product was made in China.

Cheap and fake

Part of the problem is that drug ingredients may come from multiple sources. Not all countries monitor quality or demand drugs meet consistent standards. That has plagued efforts to solve the issue: The report noted that disagreements, including about definitions, have "hampered coordinated efforts."

Cost is another issue. "Because the cost of the active ingredient represents the lion's share of the medicine's price, scrimping even modestly on the active ingredient can vastly boost profit," they wrote. "Costs can be shaved in other ways as well: by not rigorously cleaning equipment between runs, which can result in contaminated drugs or by failing to invest in adequate water filtration systems, which ratchets up the risk of microbial growth."

The group said crime and corruption drive the fake medicine business. "Falsifying medicines has been called the 'perfect crime' because the cost of making a fake drug is minimal and often leaves no paper tail, making it difficult to investigate and prosecute," the report said. "Spotting a fake medicine requires specialized skills and equipment since legitimate and illegitimate products often are indistinguishable and mix freely in unregulated markets."

According to the IOM, the impact is felt most strongly by low- and middle-income countries, where the cost of medications makes up as much as 60 percent of health spending and 90 percent of the people pay for the medications they need themselves. The report said that a month's worth of the least expensive generic ulcer medication costs more than three days' wages for an average government employee in many regions such as Africa, Eastern Europe and the Middle East.

Hard to regulate

Online pharmacies pose their own problems in the system, the report noted, because people look for low-cost options and may not know what they're actually ordering or the quality of medication they will receive. Effort to change that would focus on alerting consumers to the risks, since there are no obvious ways to control Internet drug sales or monitor or enforce quality in what people order.

That's one reason the panel that wrote the report has concluded the solution will take international agreement.

Try out the new DeseretNews.com design!
try beta learn more
Get The Deseret News Everywhere